Fourth Quarter 2022 and Subsequent Highlights: Announced topline results from Phase 1 study of RT-102. In December 2022, Rani announced topline results from Part 2 (repeat-dose portion) of the ...

Rani Therapeutics Holdings ... a lack of independent advancements or breakthroughs in their own product pipeline. The inclusion of forward-looking statements highlights potential risks and ...

Rani Therapeutics Holdings ... and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti ...

Additionally, Rani Therapeutics’ interest in expanding its pipeline to include an obesity program, which is backed by encouraging preclinical studies showing comparable weight loss effects to ...

Despite the revised timeline, Canaccord Genuity maintained a Buy rating on the company's shares, indicating its continued confidence in the potential of Rani Therapeutics' pipeline. These are the ...

Rani Therapeutics is a clinical stage biotech ... and highlight the important advancements that Rani has achieved in its pipeline over the past year. Then I will share how we are leveraging ...

Rani Therapeutics also announced its anticipation for a Phase 1 clinical trial in 2025 for RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, developed in partnership with ProGen.

The firm's pipeline includes RT-114, a RaniPill capsule containing a dual-agonist for GLP-1 and GLP-2, named PG-102. Rani Therapeutics is preparing to initiate a Phase 1 trial for RT-114.